Key result
High output in group 1 PH linked to ~110% higher mortality and adverse cardiac remodeling.
Why the study?
Pulmonary vasodilators increase cardiac output in group 1 PH and can cause high cardiac output with unclear implications.
Does a high output state driven by intensive vasodilator therapy increase the risk of death or transplant in patients with group 1 pulmonary hypertension?
Population
449 PVDOMICS group 1 PH participants and a validation cohort of 37
Comparison
Low output vs normal output vs high output
Design
Cohort study with validation cohort
Authors
Loading...
High output in group 1 PH may reflect vasodilator overuse; leaves open whether dose reduction improves survival.
Does a high output state driven by intensive vasodilator therapy increase the risk of death or transplant in patients with group 1 pulmonary hypertension?
In patients with group 1 pulmonary hypertension, a high output state driven by intensive vasodilator therapy is associated with adverse cardiac remodeling and a 2.1-fold increased risk of death or transplant.
Reddy et al. (2026) studied this question. High output occurs in 9% of group 1 PH patients, linked to vasodilator use and higher mortality (adjusted HR 2.1), with adverse cardiac remodeling and workload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: